Rapt Therapeutics (United States)

Selective γ8 transmembrane α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor regulatory protein negative allosteric modulators: Efficacy in preclinical antiseizure models

Abstract Objective RAP‐219, a potent selective negative allosteric modulator (NAM) of α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor (AMPAR) associated with γ8 transmembrane AMPAR regulatory protein (TARPγ8), is in phase 3 development for refractory focal epilepsy....